NEOadjuvant Ipi Nivo Rela for Melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have melanoma that can be surgically removed with clear margins.
- You must be in good general health (ECOG score 0-1).
- You must agree to have a new biopsy of your tumor.
- You cannot have had certain previous treatments (varies by group).
- You cannot have active autoimmune disease, serious infections, or recent heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.